Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| URGN | 8-K | neutral | 3/10 | UroGen Pharma held its 2026 annual meeting of shareholders on June 22, 2026. Shareholders approved election of all 7 dir | Jun 23, 2026 |
| AGMB | 6-K | neutral | 5/10 | Agomab announced the design of its Phase 2b NOV-ERA study for ontunisertib in Fibrostenosing Crohn's Disease, with FDA a | Jun 23, 2026 |
| ALTO | 8-K | neutral | 3/10 | Alto Ingredients filed an 8-K confirming stockholder approval of the 2026 Omnibus Incentive Plan and the election of fiv | Jun 23, 2026 |
| ADTX | 8-K | bearish | 6/10 | Aditxt amended its June 3 Note Purchase Agreement to increase the aggregate principal of senior secured convertible note | Jun 23, 2026 |
| ICLR | 6-K | neutral | 5/10 | { "summary": "ICON reports Q1 2026 results with nearly flat revenue (+0.9% to $2.03B), but a sharp decline in profitab | Jun 23, 2026 |
| NUVB | 144 | neutral | 3/10 | Insider Kerry Wentworth (Officer) filed a Form 144 on June 23, 2026, signaling intent to sell 63,000 shares (~$362,880 a | Jun 23, 2026 |
| TLPH | 8-K | neutral | 2/10 | Talphera reported the results of its 2026 Annual Meeting on June 22, 2026, at which all five stockholder proposals passe | Jun 23, 2026 |
| SLN | 8-K | neutral | 3/10 | Silence Therapeutics filed an updated corporate presentation on June 23, 2026, highlighting pipeline progress across its | Jun 23, 2026 |
| IFF | 8-K | neutral | 4/10 | International Flavors & Fragrances entered into a $1.0 billion senior unsecured delayed draw term loan facility to refin | Jun 23, 2026 |
| ICLR | 6-K | bearish | 6/10 | ICON's Q1 2026 6-K shows modest revenue growth of 0.9% but a steep 35% decline in net income to $104.8M and EPS drop fro | Jun 23, 2026 |
| NTHI | 8-K | bullish | 5/10 | NeOnc Technologies announced that the Department of Health Abu Dhabi (DOH) granted IND status for its lead candidate NEO | Jun 23, 2026 |
| SXT | 8-K | neutral | 3/10 | Sensient Technologies entered into a $400M unsecured delayed-draw term loan credit agreement with CoBank as administrati | Jun 23, 2026 |
| TBPH | 8-K | neutral | 2/10 | Theravance Biopharma disclosed the planned departure of SVP Development and Head of Ireland Office, Dr. ine Miller, effe | Jun 23, 2026 |
| CBIO | CLUSTER | neutral | 4/10 | Seven insiders at Crescent BioPharma, including CEO Joshua Brumm and President/COO Jonathan McNeill, sold shares on June | Jun 23, 2026 |
| ARGX | 6-K | neutral | 4/10 | Argenx announced a webinar on advancing FcRn leadership into autoimmune myositis, featuring key opinion leaders. While t | Jun 23, 2026 |
| ZSQR | EFFECT | bearish | 7/10 | The SEC declared effective the S-1 registration statement for Z Squared Inc., allowing selling securityholders to immedi | Jun 23, 2026 |
| CRVO | 424B5 | bearish | 6/10 | CervoMed is offering 2,500,000 shares of common stock at $4.00 per share via a best-efforts placement agent (H.C. Wainwr | Jun 22, 2026 |
| KYMR | CLUSTER | neutral | 3/10 | Two Kymera insiders (Director Bruce Booth and CBO Noah Goodman) sold a combined $1.62M in open-market shares over a 7-da | Jun 22, 2026 |
| PLUR | 8-K | mixed | 5/10 | Pluri Inc. received a $1.25M advance from its chairman, Alexandre Weinstein, via Chutzpah Holdings LP, to be credited to | Jun 22, 2026 |
| PBM | 20-F | bearish | 6/10 | Psyence Biomedical filed its annual 20-F for FY2026, reporting a net loss of $6.89 million (vs. $1 million profit in FY2 | Jun 22, 2026 |
| ALLO | 424B5 | bearish | 6/10 | Allogene Therapeutics filed a 424B5 prospectus supplement for an at-the-market (ATM) common stock offering of up to $135 | Jun 22, 2026 |
| RDHL | 6-K | bearish | 7/10 | RedHill Biopharma is conducting a private placement of ADSs and warrants for an undisclosed aggregate amount, with H.C. | Jun 22, 2026 |
| ANAB | 8-K | neutral | 2/10 | AnaptysBio entered into a sublease agreement with First Tracks Biotherapeutics for approximately 45,057 rentable square | Jun 22, 2026 |
| ORIC | 8-K | neutral | 3/10 | ORIC Pharmaceuticals filed an 8-K reporting the stockholder-approved amendment and restatement of its 2020 Equity Incent | Jun 22, 2026 |
| ALLO | 8-K | bearish | 6/10 | Allogene Therapeutics held its 2026 Annual Meeting on June 18, 2026, where stockholders approved an amendment to increas | Jun 22, 2026 |
| SPRO | 8-K | bullish | 8/10 | Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipenem pivoxil), the first oral carbapenem antibiotic fo | Jun 22, 2026 |
| BBOT | 8-K | neutral | 2/10 | BridgeBio Oncology Therapeutics filed an 8-K reporting the resignation of board member Michelle Doig effective June 16, | Jun 22, 2026 |
| TRAX | 8-K | neutral | 2/10 | First Tracks Biotherapeutics entered into a 12-month sublease agreement with AnaptysBio for approximately 45,057 square | Jun 22, 2026 |
| ADPT | 8-K | mixed | 6/10 | Adaptive Biotechnologies issued $345M in 0% convertible senior notes due 2031, used $156.9M to repurchase and terminate | Jun 22, 2026 |
| ARVN | 8-K | neutral | 3/10 | Arvinas (ARVN) filed an 8-K announcing the departure of Chief Medical Officer Dr. Noah Berkowitz, effective July 3, 2026 | Jun 22, 2026 |